Evidence-based treatment of delirium in patients with cancer

Journal of Clinical Oncology

Volumn 30, Issue 11, 2012, Pages 1206-1214

  Breitbart, William ^a   Alici, Yesne ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Central Regional Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; DEXMEDETOMIDINE; DONEPEZIL; HALOPERIDOL; LORAZEPAM; MELATONIN; METHYLPHENIDATE; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; ZIPRASIDONE; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; NEUROLEPTIC AGENT;

ADVANCED CANCER; AKATHISIA; CANCER PATIENT; COGNITIVE DEFECT; DELIRIUM; DRUG DOSE REDUCTION; DSM-IV-TR; ELECTROENCEPHALOGRAM; EVIDENCE BASED PRACTICE; EXTRAPYRAMIDAL SYMPTOM; FUNCTIONAL NEUROIMAGING; HUMAN; HYPOTENSION; LEUKEMIA; LOW DRUG DOSE; LUMBAR PUNCTURE; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHENOMENOLOGY; PREVALENCE; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEDATION; SIDE EFFECT; TERMINALLY ILL PATIENT; NEOPLASM; PSYCHOLOGICAL ASPECT;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ANTIPSYCHOTIC AGENTS; CHOLINESTERASE INHIBITORS; DELIRIUM; EVIDENCE-BASED PRACTICE; HUMANS; NEOPLASMS; PREVALENCE;

EID: 84861561435     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.8784     Document Type: Review

References (78)

1. Breitbart W, Gibson C, Tremblay A: The delirium experience: Delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses/caregivers, and their nurses. Psychosomatics 43:183-194, 2002
2. Morita T, Hirai K, Sakaguchi Y, et al: Family-perceived distress from delirium-related symptoms of terminally ill cancer patients. Psychosomatics 45:107-113, 2004
3. Inouye SK: Delirium in older persons. N Engl J Med 354:1157-1165, 2006
4. Witlox J, Kalisvaart KJ, de Jonghe JF, et al: Cerebrospinal fluid β-amyloid and tau are not associated with risk of delirium: A prospective cohort study in older adults with hip fracture. J Am Geriatr Soc 59:1260-1267, 2011
5. Bruera E, Fainsinger RL, Miller MJ, et al: The assessment of pain intensity in patients with cognitive failure: A preliminary report. J Pain Symptom Manage 7:267-270, 1992
6. Gagnon B, Lawlor PG, Mancini IL, et al: The impact of delirium on the circadian distribution of breakthrough analgesia in advanced cancer patients. J Pain Symptom Manage 22:826-833, 2001
7. Breitbart W, Alici Y: Agitation and delirium at the end of life: "We couldn't manage him." JAMA 300:2898-2910, 2008
8. Fann JR, Roth-Roemer S, Burington BE, et al: Delirium in patients undergoing hematopoietic stem cell transplantation. Cancer 95:1971-1981, 2002
9. Gaudreau JD, Gagnon P, Harel F, et al: Psychoactive medications and risk of delirium in hospitalized cancer patients. J Clin Oncol 23:6712-6718, 2005
10. Lawlor PG, Gagnon B, Mancini IL, et al: Occurrence, causes, and outcome of delirium in patients with advanced cancer: A prospective study. Arch Intern Med 160:786-794, 2000
11. Morita T, Tei Y, Tsunoda J, et al: Underlying pathologies and their associations with clinical features in terminal delirium of cancer patients. J Pain Symptom Manage 22:997-1006, 2001
12. Spiller JA, Keen JC: Hypoactive delirium: Assessing the extent of the problem for inpatient specialist palliative care. Palliat Med 20:17-23, 2006
13. [No authors listed]: Practice guideline for the treatment of patients with delirium: American Psychiatric Association. Am J Psychiatry 156:1-20, 1999
14. Trzepacz PT, Sclabassi RJ, Van Thiel DH: Delirium: A subcortical phenomenon? J Neuropsychiatry Clin Neurosci 1:283-290, 1989
15. Trzepacz PT: Is there a final common neural pathway in delirium? Focus on acetylcholine and dopamine. Semin Clin Neuropsychiatry 5:132-148, 2000
16. Maldonado JR: Pathoetiological model of delirium: A comprehensive understanding of the neurobiology of delirium and an evidence-based approach to prevention and treatment. Crit Care Clin 24:789-856, 2008
17. Boettger S, Breitbart W: Phenomenology of the subtypes of delirium: Phenomenological differences between hyperactive and hypoactive delirium. Palliat Support Care 9:129-135, 2011
18. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders DSMIV- TR (ed 4; Text Revision). Washington, DC, American Psychiatric Association Press, 2000
19. Breitbart W, Rosenfeld B, Roth A, et al: The Memorial Delirium Assessment Scale. J Pain Symptom Manage 13:128-137, 1997
20. Trzepacz PT, Mittal D, Torres R, et al: Validation of the Delirium Rating Scale-revised-98: Comparison with the delirium rating scale and the cognitive test for delirium. J Neuropsychiatry Clin Neurosci 13:229-242, 2001
21. Inouye SK, van Dyck CH, Alessi CA, et al: Clarifying confusion: The confusion assessment method - A new method for the detection of delirium. Ann Intern Med 113:941-948, 1990
22. Smith MJ, Breitbart WS, Platt MM: A critique of instruments and methods to detect, diagnose, and rate delirium. J Pain Symptom Manage 10:35-77, 1994
23. Meagher DJ, Moran M, Raju B, et al: Motor symptoms in 100 patients with delirium versus control subjects: Comparison of subtyping methods. Psychosomatics 49:300-308, 2008
24. Stagno D, Gibson C, Breitbart W: The delirium subtypes: A review of prevalence, phenomenology, pathophysiology, and treatment response. Palliat Support Care 2:171-179, 2004
25. Boettger S, Friedlander M, Breitbart W, et al: Aripiprazole and haloperidol in the treatment of delirium. Aust N Z J Psychiatry 45:477-482, 2011
26. Breitbart W, Tremblay A, Gibson C: An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics 43: 175-182, 2002
27. Breitbart W, Marotta R, Platt MM, et al: A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 153:231-237, 1996
28. Kiely DK, Jones RN, Bergmann MA, et al: Association between psychomotor activity delirium subtypes and mortality among newly admitted post-acute facility patients. J Gerontol A Biol Sci Med Sci 62:174-179, 2007
29. National Comprehensive Cancer Network Distress Management Panel Members: National Comprehensive Cancer Network (v. 1.2011) distress management - NCCN practice guidelines in oncology. http://www.nccn.org/professionals/physician- gls/pdf/ distress.pdf
30. Agar M, Currow D, Plummer J, et al: Changes in anticholinergic load from regular prescribed medications in palliative care as death approaches. Palliat Med 23:257-265, 2009
31. Boettger S, Breitbart W: Atypical antipsychotics in the management of delirium: A review of the empirical literature. Palliat Support Care 3:227-237, 2005
32. Lonergan E, Britton AM, Luxenberg J, et al: Antipsychotics for delirium. Cochrane Database Syst Rev 2:CD005594, 2007
33. Jackson KC, Lipman AG: Drug therapy for delirium in terminally ill patients. Cochrane Database Syst Rev 2:CD004770, 2004
34. Han CS, Kim YK: A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics 45:297-301, 2004
35. Hu H, Deng W, Yang H: A prospective random control study: Comparison of olanzapine and haloperidol in senile delirium. Chongqing Med J 8:1234-1237, 2004
36. Grover S, Kumar V, Chakrabarti S: Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. J Psychosom Res 71:277-281, 2011
37. Girard TD, Pandharipande PP, Carson SS, et al: Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: The MIND randomized, placebo-controlled trial. Crit Care Med 38:428-437, 2010
38. Devlin JW, Roberts RJ, Fong JJ, et al: Efficacy and safety of quetiapine in critically ill patients with delirium: A prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. Crit Care Med 38:419-427, 2010
39. Tahir TA, Eeles E, Karapareddy V, et al: A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. J Psychosom Res 69:485-490, 2010
40. Elsayem A, Bush SH, Munsell MF, et al: Subcutaneous olanzapine for hyperactive or mixed delirium in patients with advanced cancer: A preliminary study. J Pain Symptom Manage 40:774-782, 2010
41. Kim SW, Yoo JA, Lee SY, et al: Risperidone versus olanzapine for the treatment of delirium. Hum Psychopharmacol 25:298-302, 2010
42. Kim KY, Bader GM, Kotlyar V, et al: Treatment of delirium in older adults with quetiapine. J Geriatr Psychiatry Neurol 16:29-31, 2003
43. Flaherty JH: The evaluation and management of delirium among older persons. Med Clin North Am 95:555-577, 2011
44. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596-601, 2004
45. Harrigan EP, Miceli JJ, Anziano R, et al: A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 24: 62-69, 2004
46. Haddad PM, Anderson IM: Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 62:1649-1671, 2002
47. US Food and Drug Administration: Information for healthcare professionals: Haloperidol (marketed as Haldol, Haldol Decanoate and Haldol Lactate). http:// www.fda.gov/Drugs/DrugSafety/PostmarketDrug SafetyInformationforPatientsandProviders/Drug SafetyInformationforHeathcareProfessionals/ucm 085203.htm
48. Schneider LS, Dagerman KS, Insel P: Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA 294:1934-1943, 2005
49. Wang PS, Schneeweiss S, Avorn J, et al: Risk of death in elderly users of conventional vs atypical antipsychotic medications. N Engl J Med 353:2335-2341, 2005
50. US Food and Drug Administration: Information for healthcare professionals: Conventional Anti-psychotics. http://www.fda.gov/drugs/ drugsafety/ postmarketdrugsafetyinformationforpatientsand providers/ucm124830. htm
51. Elie M, Boss K, Cole MG, et al: A retrospective, exploratory, secondary analysis of the association between antipsychotic use and mortality in elderly patients with delirium. Int Psychogeriatr 21: 588-592, 2009
52. Gagnon B, Low G, Schreier G: Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: A prospective clinical study. J Psychiatry Neurosci 30:100-107, 2005
53. Keen JC, Brown D: Psychostimulants and delirium in patients receiving palliative care. Palliat Support Care 2:199-202, 2004
54. Morita T, Otani H, Tsunoda J, et al: Successful palliation of hypoactive delirium due to multi-organ failure by oral methylphenidate. Support Care Cancer 8:134-137, 2000
55. Overshott R, Karim S, Burns A: Cholinesterase inhibitors for delirium. Cochrane Database Syst Rev 1:CD005317, 2008
56. Overshott R, Vernon M, Morris J, et al: Rivastigmine in the treatment of delirium in older people: A pilot study. Int Psychogeriatr 22:812-818, 2010
57. van Eijk MM, Roes KC, Honing ML, et al: Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: A multicentre, double-blind, placebocontrolled randomised trial. Lancet 376:1829-1837, 2010
58. Liptzin B, Laki A, Garb JL, et al: Donepezil in the prevention and treatment of post-surgical delirium. Am J Geriatr Psychiatry 13:1100-1106, 2005
59. Sampson EL, Raven PR, Ndhlovu PN, et al: A randomized, double-blind, placebo-controlled trial of donepezil hydrochloride (Aricept) for reducing the incidence of postoperative delirium after elective total hip replacement. Int J Geriatr Psychiatry 22:343-349, 2007
60. Inouye SK, Bogardus ST Jr, Charpentier PA, et al: A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med 340:669-766, 1999
61. Siddiqi N, Stockdale R, Britton AM, et al: Interventions for preventing delirium in hospitalised patients. Cochrane Database Syst Rev 2:CD005563, 2007
62. Marcantonio ER, Flacker JM, Wright RJ, et al: Reducing delirium after hip fracture: A randomized trial. J Am Geriatr Soc 49:516-522, 2001
63. Pandharipande PP, Sanders RD, Girard TD, et al: Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: An a prioridesigned analysis of the MENDS randomized controlled trial. Crit Care 14:R38, 2010
64. Riker RR, Shehabi Y, Bokesch PM, et al: Dexmedetomidine vs midazolam for sedation of critically ill patients: A randomized trial. JAMA 301: 489-499, 2009
65. Al-Aama T, Brymer C, Gutmanis I, et al: Melatonin decreases delirium in elderly patients: A randomized, placebo-controlled trial. Int J Geriatr Psychiatry 26:687-694, 2011
66. Kalisvaart KJ, de Jonghe JF, Bogaards MJ, et al: Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: A randomized placebo-controlled study. J Am Geriatr Soc 53:1658-1666, 2005
67. Larsen KA, Kelly SE, Stern TA, et al: Administration of olanzapine to prevent postoperative delirium in elderly joint-replacement patients: A randomized, controlled trial. Psychosomatics 51: 409-418, 2010
68. Prakanrattana U, Prapaitrakool S: Efficacy of risperidone for prevention of postoperative delirium in cardiac surgery. Anaesth Intensive Care 35:714-719, 2007
69. National Institute for Health and Clinical Excellence: Delirium: Diagnosis, prevention and management (NICE clinical guideline 103). July 2010. www .nice.org.uk/nicemedia/live/13060/49909/49909.pdf
70. Gamberini M, Bolliger D, Lurati Buse GA, et al: Rivastigmine for the prevention of postoperative delirium in elderly patients undergoing elective cardiac surgery: A randomized controlled trial. Crit Care Med 37:1762-1768, 2009
71. Prommer E: Review article: Dexmedetomidine: Does it have potential in palliative medicine? Am J Hosp Palliat Care 28:276-283, 2011
72. Cole MG, Primeau FJ, Bailey RF, et al: Systematic intervention for elderly inpatients with delirium: A randomized trial. CMAJ 151:965-970, 1994
73. Cole MG, McCusker J, Bellavance F, et al: Systematic detection and multidisciplinary care of delirium in older medical inpatients: A randomized trial. CMAJ 167:753-759, 2002
74. Pitkälä KH, Laurila JV, Strandberg TE, et al: Multicomponent geriatric intervention for elderly inpatients with delirium: A randomized, controlled trial. J Gerontol A Biol Sci Med Sci 61:176-181, 2006
75. Flaherty JH, Steele DK, Chibnall JT, et al: An ACE unit with a delirium room may improve function and equalize length of stay among older delirious medical inpatients. J Gerontol A Biol Sci Med Sci 65:1387-1392, 2010
76. Pitkala KH, Laurila JV, Strandberg TE, et al: Multicomponent geriatric intervention for elderly inpatients with delirium: Effects on costs and health-related quality of life. J Gerontol A Biol Sci Med Sci 63:56-61, 2008
77. Milisen K, Lemiengre J, Braes T, et al: Multi-component intervention strategies for managing delirium in hospitalized older people: Systematic review. J Adv Nurs 52:79-90, 2005
78. Gagnon P, Allard P, Gagnon B, et al: Delirium prevention in terminal cancer: Assessment of a multi-component intervention. Psychooncology 21:187-194, 2012